Management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in Togo

Abstract

Prise en charge des hyperparathyroïdies secondaires chez des patients dialysés au Togo

Comparison of two parathyroid hormone (pth) assay methods in the monitoring of black african hemodialysis patients in the ivory coast (Maglumi® vs Vidas Biomerieux® Kits)

“…11 The predominant age group in our series is [40-50[years with a frequency of 40% with a mean age of 47 years and extremes from 20 to 75 years. These results are similar to those also observed in Côte d'Ivoire in 2016 by Kropka A. et al 12 with a mean age of 45 years and extremes of 18 to 74 years, in Togo with a mean age of 42.62 years and extremes of 20 and 82 years in the study conducted by Dosseh et al 13 in patients also with chronic renal failure at the dialysis stage. This value was slightly higher in Morocco in 2012, with an average age of 49.3 years in the study by Hasni et al, 14 and even higher in France, where the average age of dialysis patients reached 65 years in the study by Masse et al 15 This finding could be explained by better access to healthcare for populations in Maghreb and developed countries, compared with populations in sub-Saharan francophone Africa.…”

Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: a systematic review

“…27 Use of phosphate binders was reported in two of 42 and 19 of 45 patients in two adult studies. 28,29 Haemodialysis vascular access was described in 22 adult studies. Overall, the mean proportion of patients with arteriovenous fistula was 15•6% [SD 9 •7] at the start of dialysis, but rose among prevalent patients over time (from 16•5% [10•9] to 61•3% [26•2]; appendix p 16).…”